Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.770
+0.160 (9.94%)
At close: Nov 6, 2026, 4:00 PM EST
1.790
+0.020 (1.13%)
After-hours: Nov 6, 2026, 7:30 PM EST
Lexicon Pharmaceuticals Employees
Lexicon Pharmaceuticals had 81 employees as of December 31, 2025. The number of employees decreased by 22 or 21.36% compared to the previous year. That makes Lexicon Pharmaceuticals the 32,663rd largest employer in the world and 4,255th in the United States.
Employees
81
Change (1Y)
-22
Growth (1Y)
-21.36%
Revenue / Employee
$475,765
Profits / Employee
-$769,790
Market Cap
787.57M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 81 | -22 | -21.36% |
| Dec 31, 2024 | 103 | -182 | -63.86% |
| Dec 31, 2023 | 285 | 150 | 111.11% |
| Dec 31, 2022 | 135 | 48 | 55.17% |
| Dec 31, 2021 | 87 | 9 | 11.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Geron | 258 |
| 4D Molecular Therapeutics | 196 |
| DBV Technologies | 170 |
| Olema Pharmaceuticals | 150 |
| Helus Pharma | 100 |
| Apnimed | 81 |
| ArriVent BioPharma | 77 |
| Design Therapeutics | 55 |
LXRX News
- 1 day ago - Lexicon Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 1 day ago - Lexicon Pharmaceuticals Earnings release: Q3 2026 - Filings
- 1 day ago - Lexicon Pharmaceuticals Slides: Q3 2026 - Filings
- 1 day ago - Lexicon Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 1 day ago - Lexicon reports Q3 EPS (3c), consensus (5c) - TheFly
- 1 day ago - Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates - GlobeNewsWire
- 8 days ago - Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026 - GlobeNewsWire
- 14 days ago - Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy - GlobeNewsWire